From a set of more than 20 macrolide based chemical compounds, engineered to lose antimicrobial activities and obtain enhanced immune activating properties, we have identified ISR050 as our lead compound. Our IP protected Immunolide, ISR050, has enhanced immune-stimulatory properties of antigen presenting cells making ISR050 a valuable tool to treat cancer. We have now tested ISR050 in animal models of cancer and found a decreased tumor volume after treatment with ISR050 used in combination with check point inhibitors. Thus, our novel immunolide ISR050 targeting antigen presenting cells adds synergistically to the already proven effect of targeting T cells by check point inhibitors by decreasing tumour cell growth. The company is now intensifying its immuno-oncology development program and ISR050 is now undergoing safety/toxicity testing in an IND program, with the aim to bring it to clinical trial late 2018.
Cancer is not the main target research area for ISR and for that reason the board has decided to establish a separate subsidiary, focusing on the cancer indication. ISR will look for interested partners to join and finance the continued research programme.
"ISR is now intensifying its immuno-oncology programme on our developed Immunolide ISR050, which has great potential to enhance the immune response against cancer"
comment Ola Winqvist, CEO ISR

For additional information, please contact:
Ola Winqvist, CEO, ISR Immune System Regulation Holding AB
E-mail:ola.winqvist@israb.se
Ph:  +46 (0)70 5427939
Denna information är sådan information som ISR Immune System Regulation Holding AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 26 mars 2018 kl. 08:07 CET.